Drug intelligence / Profile preview

Jiawei Huanshao Dan

Development stage: Unknown
Lead developer: China-Japan Friendship Hospital
Administration: Oral

Overview

Jiawei Huanshao Dan is a modified Traditional Chinese Medicine (TCM) formulation based on the classic Huanshao Dan (Return to Youth Pill) prescription. It is currently under clinical investigation by the China-Japan Friendship Hospital for the management of senile frailty syndrome and cognitive impairment in the elderly. The drug is designed to address the multi-system decline associated with aging by modulating inflammatory pathways and immune responses. In clinical trial settings, it is evaluated for its ability to improve physical function and cognitive status compared to placebo, with a focus on its efficacy, safety, and underlying mechanisms related to inflammation and immune regulation.

Other names: Jiawei Huanshao Dan

Beyond the preview

Go deeper on Jiawei Huanshao Dan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiawei Huanshao Dan.

Explore the full profile